Table 3. Adjuvant treatment for patients with WHO grade 3 anaplastic astrocytoma, IDH-mutant by KSNO, NCCN, and EANO guideline.

Guidelines	Adjuvant treatment
KSNO	1) Standard RT & followed adjuvant temozolomide chemotherapy
	2) Standard RT with concurrent and adjuvant temozolomide chemotherapy
	3) Standard RT with neoadjuvant or adjuvant PCV chemotherapy
	4) Standard RT alone
NCCN	- For patients with KPS ≥60
		1) Standard RT & followed adjuvant temozolomide chemotherapy
		2) Standard RT with concurrent & adjuvant temozolomide chemotherapy
	- For patients with KPS <60
		1) RT (hypofractionated)
		2) Temozolomide (category 2B)
		3) Palliative/best supportive care
EANO	RT (54–60 Gy in 1.8–2.0 Gy fractions) followed by temozolomide (or wait-and-see)

EANO, European Association of Neuro-Oncology; KPS, Karnofsky Performance Scale; KSNO, Korean Society for Neuro-Oncology; NCCN, National Comprehensive Cancer Network; PCV, procarbazine, CCNU, and vincristine; RT, radiotherapy; WHO, World Health Organization